Investigating PSMA-PET/CT to resolve prostate MRI PIRADS4-5 and negative biopsy discordance

LM Wong; S Koschel; T Whish-Wilson; M Farag; D Bolton; H Zargar; N Corcoran; N Lawrentschuk; A Christov; L Thomas; E Perry; S Heinze; K Taubman; T Sutherland

Journal article

Investigating PSMA-PET/CT to resolve prostate MRI PIRADS4-5 and negative biopsy discordance

LM Wong, S Koschel, T Whish-Wilson, M Farag, D Bolton, H Zargar, N Corcoran, N Lawrentschuk, A Christov, L Thomas, E Perry, S Heinze, K Taubman, T Sutherland

World Journal of Urology | SPRINGER | Published : 2023

DOI: 10.1007/s00345-022-04243-5

Abstract

Background: To determine the utility of diagnostic 18F-DCPyL PSMA-PET/CT to aid management of men with highly suspicious multiparametric MRI prostate (PIRAD 4–5 lesions) and discrepant negative prostate biopsy. Methods: A multicentre prospective consecutive case series was conducted (2018–2021), recruiting men with prior mpMRI prostate PIRADS 4–5 lesions and negative prostate biopsy. All men had 18F-DCPyL PSMA-PET/CT with subsequent management based on the concordance between MRI and PET: (1) Concordant lesions were biopsied using in-bore MRI targeting; (2) PSMA-PET/CT avidity without MRI correlate were biopsied using cognitive/software targeting with ultrasound guidance and (3) Patients wit..

View full abstract

University of Melbourne Researchers

Ming Wong Author

Damien Bolton Author

Niall Corcoran Author

Nathan Lawrentschuk Author

Grants

Funding Acknowledgements

This clinical trial is supported by Cyclotek (Aust) Pty Ltd and their key partners, the Australian Government as part of its CRC Projects Program, General Electrical Healthcare and Macquarie University. Dr. Samantha Koschel is supported by a Research Training Program Scholarship from the Australian Government. We also acknowledge the support of the St Vincent's Research Endowment fund.